Shaw S - Search Results

1

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.

Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S. Glatt S, et al. Among authors: shaw s. Ann Rheum Dis. 2018 Apr;77(4):523-532. doi: 10.1136/annrheumdis-2017-212127. Epub 2017 Dec 23. Ann Rheum Dis. 2018. PMID: 29275332 Free PMC article. Clinical Trial.

2

Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.

Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A. Shaw S, et al. MAbs. 2014 May-Jun;6(3):774-82. doi: 10.4161/mabs.28612. Epub 2014 Apr 2. MAbs. 2014. PMID: 24670876 Free PMC article.

3

Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.

Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, Jose J, Oliver R. Kretsos K, et al. Among authors: shaw s. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi: 10.1002/cpdd.121. Epub 2014 May 26. Clin Pharmacol Drug Dev. 2014. PMID: 27129012 Clinical Trial.

4

First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.

Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, Harari OA, Lambert J, Shaw S. Glatt S, et al. Among authors: shaw s. Br J Clin Pharmacol. 2017 May;83(5):991-1001. doi: 10.1111/bcp.13185. Epub 2017 Jan 10. Br J Clin Pharmacol. 2017. PMID: 27859546 Free PMC article. Clinical Trial.

5

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.

Glatt S, Taylor PC, McInnes IB, Schett G, Landewé R, Baeten D, Ionescu L, Strimenopoulou F, Watling MIL, Shaw S. Glatt S, et al. Among authors: shaw s. Ann Rheum Dis. 2019 Aug;78(8):1033-1040. doi: 10.1136/annrheumdis-2018-214943. Epub 2019 Jun 8. Ann Rheum Dis. 2019. PMID: 31177099 Free PMC article. Clinical Trial.

6

Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis.

Chen S, Blijdorp IC, van Mens LJJ, Bowcutt R, Latuhihin TE, van de Sande MGH, Shaw S, Yeremenko NG, Baeten DLP. Chen S, et al. Among authors: shaw s. J Rheumatol. 2020 Nov 1;47(11):1606-1613. doi: 10.3899/jrheum.190571. Epub 2020 Jan 15. J Rheumatol. 2020. PMID: 31941804

7

Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases.

Chen S, Paveley R, Kraal L, Sritharan L, Stevens E, Dedi N, Shock A, Shaw S, Juarez M, Yeremenko N, Baeten D, Payne A. Chen S, et al. Among authors: shaw s. J Autoimmun. 2020 Jul;111:102435. doi: 10.1016/j.jaut.2020.102435. Epub 2020 Apr 29. J Autoimmun. 2020. PMID: 32360069 Free article.

8

Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells.

Shah M, Maroof A, Gikas P, Mittal G, Keen R, Baeten D, Shaw S, Roberts SJ. Shah M, et al. Among authors: shaw s. RMD Open. 2020 Jul;6(2):e001306. doi: 10.1136/rmdopen-2020-001306. RMD Open. 2020. PMID: 32723833 Free PMC article.

9

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.

Adams R, Maroof A, Baker T, Lawson ADG, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, Griffiths M. Adams R, et al. Among authors: shaw s. Front Immunol. 2020 Aug 21;11:1894. doi: 10.3389/fimmu.2020.01894. eCollection 2020. Front Immunol. 2020. PMID: 32973785 Free PMC article.

10

Interleukin (IL)-12 and IL-18 Synergize to Promote MAIT Cell IL-17A and IL-17F Production Independently of IL-23 Signaling.

Cole S, Murray J, Simpson C, Okoye R, Tyson K, Griffiths M, Baeten D, Shaw S, Maroof A. Cole S, et al. Among authors: shaw s. Front Immunol. 2020 Nov 20;11:585134. doi: 10.3389/fimmu.2020.585134. eCollection 2020. Front Immunol. 2020. PMID: 33329560 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,011 results

Search Page

Filters